The shares of the Danish pharmaceutical company Novo Nordisk fell by more than 10 percent. This was reported by Zamin.uz.
This was due to news that the Ozempic drug, produced by the company for obesity, did not deliver the expected results in slowing down Alzheimer's disease. Nearly four thousand patients participated in two major studies conducted by Novo Nordisk.
The study results showed that the progression of Alzheimer's disease did not slow down in patients taking Ozempic. Nevertheless, some patients showed improvements in disease-related indicators.
Previously, scientists had hoped that Ozempic could be beneficial not only for diabetes and weight loss but also in the fight against Alzheimer's. The chief scientific officer of Novo Nordisk emphasized that despite the low probability of the drug's success, these studies were conducted due to the need for new medications.
During this year, the company's stock value has significantly declined. However, Eli Lilly, a US company and Novo Nordisk's main competitor, recently developed new drugs for diabetes and obesity, successfully increasing its market value to 1 trillion dollars.
